TB-500 & Thymosin Beta-4: What the Research Actually Shows

Published July 26, 2026 · Universe Peptide Research Desk

Thymosin Beta-4 (Tβ4) is one of the most studied actin-binding peptides in regenerative biology, and the synthetic fragment sold in research catalogs as TB-500 is frequently discussed alongside it. The two are related but not interchangeable, and the evidence base behind each is very different. This article maps what the peer-reviewed literature and the regulatory record currently establish — and, just as importantly, what they do not.

Tβ4 and TB-500 are not the same molecule

Thymosin Beta-4 is a 43-amino-acid protein found in most mammalian cell types. TB-500, as the term is used commercially, generally refers to a short synthetic sequence derived from the Tβ4 actin-binding region — the heptapeptide LKKTETQ — rather than to the full-length protein. This distinction matters when reading literature: the overwhelming majority of published experimental work uses full-length Tβ4, and findings from it cannot be assumed to transfer to the fragment.

The mechanism under study: actin sequestration

Tβ4's best-characterized biochemical role is as a G-actin sequestering peptide. By binding monomeric actin, it participates in regulating the polymerization dynamics that govern cell shape and migration. Because directed cell migration is upstream of essentially every tissue repair process, this single biochemical property is the origin of most downstream hypotheses in the field — including work on angiogenesis, inflammatory signaling, and remodeling. In a 2026 scoping review of the literature, angiogenesis was the single most common mechanistic focus among the studies surveyed.

What a systematic mapping of the literature found

A 2026 scoping review published in Applied Sciences mapped 80 studies across Tβ4 and TB-500. Its findings are worth stating plainly, because they are more sober than the peptide's popular reputation suggests:

• The evidence base is largely preclinical and unevenly distributed across tissues and endpoints.
• TB-500 itself is barely studied directly. The review identified a single study evaluating TB-500 specifically, and that study was a metabolite-profiling investigation rather than a tissue-repair experiment.
• What human data exists clusters in ophthalmology and dermal wound healing — not in the musculoskeletal tissues the compound is most often associated with commercially.
• The review identified no human studies examining effects on tendon, ligament, cartilage, muscle, or bone.
• Roughly a quarter of the surveyed studies reported molecular markers without an explicit mechanistic link to a healing outcome.

The authors' framing is the sentence researchers should carry out of this literature: biologic plausibility does not equal clinical proof.

The most advanced clinical program — and its most recent result

The furthest-developed Tβ4 clinical asset is RGN-259, a preservative-free 0.1% Tβ4 ophthalmic solution developed by RegeneRx Biopharmaceuticals and partner HLB Therapeutics. A randomized, placebo-controlled, double-masked Phase III trial in neurotrophic keratopathy was published in 2022 and reported improved corneal epithelial healing versus placebo in that indication.

That program has not been uniformly successful. In the dry-eye indication, the Phase 3 SEER-3 trial did not meet its primary endpoint. Any honest summary of the Tβ4 evidence has to include both results: a positive Phase III in one narrow corneal indication, and a missed primary endpoint in another. Neither outcome speaks to systemic administration or to musculoskeletal repair, and neither involves TB-500 as sold in research catalogs.

Regulatory record in the United States

Thymosin Beta-4 has no FDA approval for any indication. In the FDA's bulk drug substances record for compounding under section 503A, the Tβ4 fragment (LKKTETQ) appears among nominations that were withdrawn from consideration. In its evaluation the agency noted that compounded preparations containing the fragment may pose an immunogenicity risk for certain routes of administration, owing to aggregation potential and peptide-related impurities, and stated that it lacks important safety information about the substance — including whether it would cause harm if administered to humans. Tβ4 is additionally prohibited in sport under the World Anti-Doping Agency code.

For a laboratory, the practical reading is straightforward: this is a compound with an interesting and well-defined biochemical mechanism, a thin human evidence base, and an explicit regulatory record of unresolved safety questions. That combination is precisely why it remains a research material rather than a therapeutic.

Where the open questions are

The gaps identified in the literature are themselves the research agenda: whether the LKKTETQ fragment reproduces full-length Tβ4 activity in controlled comparisons; whether angiogenic and migratory effects observed in cell and animal models correspond to functional tissue outcomes; and whether any of the musculoskeletal hypotheses that drive popular interest survive rigorous preclinical testing. Those are open experimental questions, not settled findings.

Sources

1. Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review. Applied Sciences, 2026. mdpi.com
2. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. PubMed Central, PMC9820614. pmc.ncbi.nlm.nih.gov
3. HLB Therapeutics misses primary endpoint in Phase 3 SEER-3 trial of RGN-259. Ophthalmology Times. ophthalmologytimes.com
4. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. U.S. Food and Drug Administration. fda.gov

This article is provided for educational and informational purposes to the research community. Universe Peptide products are sold for laboratory research only, are not for human or animal consumption, and are not approved by the FDA for any therapeutic use. Buyers must be 21+.